PDCD1 and melanoma: Of patients with advanced, unresectable, or metastatic cutaneous (including one pineal gland) melanoma there were 169 total who received pembrolizumab- or nivolumab-based therapies, 100 of whom received anti-PD-1 therapies as first line therapy and 111 who received it as a single agent.